Last edition
News about "American Society of Clinical Oncology"
CHMP Recommends Imfinzi for Early Gastric Cancers
The EU’s CHMP has recommended approval of AstraZeneca’s Imfinzi perioperative regimen for early gastric and gastroesophageal cancers following positive phase-III MATTERHORN data, showing a 29 percent reduction in progression or recurrence risk and a 22 percent reduction in mortality versus chemotherapy alone.
American Society Of Clinical Oncology | 04/02/2026 | By News Bureau | 149
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
American Society Of Clinical Oncology | 29/01/2026 | By News Bureau | 218
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy